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Stimulation of f32-Adrenoceptors Inhibits Apoptosis in Rat Brain
After Transient Forebrain Ischemia We have previously demonstrated that the neuro protective effect of the i32-adrenoceptor agonist clenbuterol in vitro and in vivo was most likely mediated by an increased nerve growth factor (NGF) expression. In the present study, we examined whether clenbuterol was capable of inhibiting apop tosis caused by ischemia. Transient forebrain ischemia was performed in male Wi star rats (300 to 350 g) by clamping both common carotid arteries and reducing the blood pressure to 40 mm Hg for 10 minutes. Clenbuterol (0. 1, 0.5, and 1.0 mg/kg intraperitoneally) was administered 3 hours before ischemia or immediately after ischemia. The brains were removed for his tologic evaluation 7 days after ischemia. The time course of DNA fragmentation was determined I, 2, 3 and 4 days after ischemia. Staining with terminal deoxynucleotidyl transferase (TdT)-mediated dUTP nick end-labeling (TUNEL) was used for further analysis of DNA fragments in situ 3 days after ischemia. The NGF protein was assayed by enzyme-linked im munosorbent assay. Ten-minute forebrain ischemia damaged SO% to 90% of the neurons in the hippocampal CAl region evaluated 7 days after ischemia. Pretreatment with clenbuterol (0.5 and 1.0 mg/kg) reduced the neuronal damage by IS.I % (P The term apoptosis describes a series of morphologic changes that are different from those observed in necro sis (Kerr et aI., 1972) . Apoptosis of neurons occurs natu rally during the normal fetal and early postnatal devel opment of vertebrates. There is increasing evidence that apoptosis also is involved in neurodegenerative disorders such as Alzheimer's disease, Huntington's disease, and
Parkinson's disease (Dragunow et aI., 1995; Mochizuki et aI., 1997) . It also has been reported that apoptosis can < OJ) I) and 1 3. 1 % (P < 0.05), respectively. The neuroprotec tive effect also was found when clenbuterol (0.5 mg/kg) was administered immediately after ischemia (P < 0.05). The DNA laddering appeared in striatum I day and in hippocampus 2 days after ischemia and peaked on the third day in both regions. The DNA laddering was nearly abolished in the hippocampus and partially blocked in striatum and cortex by 0.5 mg/kg clen buterol. These results were confirmed by TUNEL staining. Clenbuterol (0.5 mg/kg intraperitoneally) elevated the NGF protein level by 33% (P < 0.05) in the hippocampus and 41 % (P < 0.05) in the cortex 6 hours after ischemia. Three days after ischemia, the NGF levels in these regions were no longer dif ferent between the clenbuterol-treated and control groups. This study clearly demonstrates that clenbuterol possesses a neuro protective activity and a marked capacity to inhibit DNA deg radation after global ischemia. The results suggest that clen buterol increases NGF expression during the first hours after global ischemia and thereby protects neurons against apoptotic damage. Key Words: i32-Adrenoceptor agonist Clenbuterol-Apoptosis-DNA fragmentation-Nerve growth factor-Transient forebrain ischemia.
be induced by various insults (Linik et aI., 1993; Mac Manus et aI., 1993; Zhai et aI., 1996) . In particular, re searchers have focused on the role of apoptotic cell death after cerebral ischemia (Kirino, 1982; Hill et aI., 1995; Linik et aI., 1995) . The demonstration of apoptosis in neurodegenerative disease and cerebral ischemia sug gests an extended window for therapeutic intervention (Linik, 1995) . Therefore, it is important to characterize new pharmacologic strategies to interfere with apoptosis effectively. Nerve growth factor (NGF) has been found to prevent developmental apoptosis (Oppenheim, 1991; Johnson and Deckwerth, 1993) . In vitro data have shown that deprivation of NGF results in neuronal death asso ciated with apoptosis (Martin et aI., 1992; Kew et aI., 1996) . In contrast, delivery of NGF prevents neuronal damage by apoptosis in vitro (Rabacchi et aI., 1994; Kawamoto et aI., 1995) as well as in vivo (Buchan et aI., 1990; Frim et aI., 1993) . However, the clinical use of NGF may be limited by its inability to cross the blood brain barrier. Catecholaminergic neurotransmitters and their analogues play a crucial role in the regulation of synthesis and secretion of NGF (Furukawa et al., 1986; Follesa and Mocchetti, 1993; Hayes et al., 1995) . Our previous studies demonstrate that stimulation of fP 2adrenergic receptor by clenbuterol, a lipophilic fP 2adrenoceptor agonist, was able to elevate both NGF mRNA and NGF protein in vitro as well as in vivo.
Moreover, c1enbuterol showed neuroprotective effects in cultured hippocampal cells and in models of cerebral ischemia (Semkova et aI., 1994; Semkova et aI., 1996a,b) . Thus, pharmacologic induction of NGF syn thesis is a potential way to increase the NGF level in brain tissue.
In the present study, we further investigated the effect 
METHODS

Transient forebrain ischemia model
Forebrain ischemia was performed in male Wistar rats (300 to 350 g, Charles River, Sulzfeld, Germany) as described pre viously with some modifications (Semkova et aI., 1996h) . The rats were fasted overnight with free access to water and anes thetized with halothane (1.5%) in a mixture of NzO/02 (70%/ 30%). Body and skull temperature were maintained at between 37.0° and 37.5°C by a temperature control feedback system (TSE, Bad Homburg, Germany). The skull temperature was monitored with a thermocouple placed subcutaneously over the midline of the skull, thereby supplying an approximate brain temperature (Corbett et aI., 1992) . Ischemia was induced for 10 minutes by clamping both common carotid arteries. The mean arterial blood pressure was lowered to 40 mm Hg by trimeth aphan camphor sulphonate (5 mg/kg intravenously) and central venous exsanguination. After 10 minutes, the clips were re moved and the blood that had been withdrawn was rapidly reinjected. Arterial pH, Pc02, Po2, blood pressure, and plasma glucose concentration were measured before and after isch emia. After the operation, the animals were kept at an environ mental temperature of 30°C for 2 hours and then at 20°C in their home cages.
For evaluation of the time course of neuronal damage in the CA 1 subfield of hippocampus, I, 2, 3, 4, and 7 days after the onset of ischemia the rats were anesthetized with a lethal dos age of chloralhydrate and perfused transcardially with saline followed by 4% phosphate-buffered formalin. The brains then were removed and embedded in paraffin. The coronal sections (5 fLM) were stained with 1 % celestine blue and 1 % acid fuch sin for histologic evaluation. Neuronal injury was evalu-ated as a percentage of damaged neurons in CAl subfield of the hippocampus. Four rats were used for each recovery time point after ischemia. In a separate experiment, the animals (n = 8 to 10 per group) received clenbuterol (0.1, 0.5, and 1.0 mg/kg intraperitoneally) or saline 3 hours before ischemia. In another series of experiments, clenbuterol (0.5 mg/kg intraperitoneally) was administered immediately after ischemia. Seven days after ischemia, the brains were removed for histologic evaluation.
Detection of DNA fragmentation
The DNA in the hippocampus, striatum and occipital cortex was individually extracted using QIAamp Tissue Kit (QIA GEN, Hilden, Germany) according to the manufacturer's pro tocol. The extracted DNA was labeled by Dig Oligonucleotide 3' -end Labeling Kit (Boehringer Mannheim, Germany). The DNA (5 fLg) was incubated with the reaction solution contain ing 4 fLL tailing buffer, 4 fLL CoCl2 solution, I fLL Dig-ddUTP solution, and I fLL terminal transferase for 15 minutes at 37°C. The reaction was terminated by 2 fLL glycogen ethylenedi amine tetraacetic acid solution. The labeled oligonucleotide was precipitated at -70°C overnight using 2.5 fLL of 4 moUL LiCI and 75 fLL prechilled (-20°C) 100% ethanol. After cen trifugation (15000 rpm, -4°C, 15 minutes), the precipitates were washed with 50 fLL of cold 70% ethanol and then dis solved in 50 fLL of sterile water.
The labeled DNA from the striatum, hippocampus, and cor tex (0.5, 1.0, and 2.0 fLg per lane, respectively) underwent electrophoresis at 100 V in 2% agarose gel containing ethidium bromide for 3 hours. The DNA was transferred from the gel onto a nylon membrane before being detected by 1% CSPD
In this experiment, one series of rat brains was removed at 1, 2, 3, and 4 days after global ischemia (n = 3 per group) for measurement of the time courses of DNA fragmentation. An other series of animals (n = 3) was treated with clenbuterol (0.5 mg/kg intraperitoneally) 3 hours before ischemia. The brains were removed 3 days after ischemia to detect DNA fragmentation.
TUNEL staining
The rats were treated with either saline or clenbuterol (0.5 mg/kg intraperitoneally) 3 hours before ischemia, and the brains were removed 3 days after ischemia. Coronal paraffin sections (0.5 f.LM) were cut from the hippocampus, striatum, and occipital cortex (-3.6 mm, 1.00 mm, and -6.30 mm to bregma, respectively) for the evaluation of cellular DNA frag mentation in situ. The TUNEL staining was performed using ApopTag Kit (Oncor, U.S.A.). Briefly, after deparaffinizing, the sections were rinsed in three changes of phosphate-buffered saline and then incubated with proteinase K (20 f.Lg/mL) for 20 minutes at room temperature. Two percent HzOz was used to quench the endogenous peroxidase activity. Afterward, the slides were incubated with working-strength TdT enzyme for 1.5 hours at 37°C followed by incubation with working strength stop/wash buffer. After incubation with two drops of antidigoxigenin-peroxidase for 30 minutes, the slides were equilibrated in 0.02% H202 for 5 minutes and then exposed to a freshly prepared staining solution containing 0.05% diami nobenzidine in 0.02% H202.
Measurement of nerve growth factor protein
The two-site NGF-ELISA was used for the measurement of NGF protein in the hippocampus, cortex, and striatum. One series of rats (n = 3 to 4 per group) was treated with c1en buterol (0.5 mg/kg intraperitoneally) 3 hours before ischemia, and the brains were removed 6 hours or 3 days after ischemia. A second series of animals (n = 3 to 4 per group) received c1enbuterol (0.5 mglkg intraperitoneally) 3 hours before isch emia and a daily injection for 3 days after ischemia. The brains were removed 3 days after ischemia. Both sides of the hippo campus, striatum, and occipital cortex were taken separately and frozen immediately on dry ice. The extraction buffer (0.1 mollL Tris-HCI, 0.4 mollL NaCI, 2% bovine serum albumin, 0.05% NaN3, 1 mmol/L phenylmethylsulfonylfluoride, 4 mmollL ethylenediamine tetraacetic acid, 7 fLg/mL trypsin in hibitor) was added to the tissue sample (19 mUg wet tissue). The tissue was homogenized and then centrifuged (20000 rpm, 4°C, 30 minutes), and the supernatant was used for NGF pro tein assay.
The ELISA was performed as described previously with some modifications (Semkova et aI., 1996b) . The wells of mi crotiter plates (MaxiSorp, Nunc, Wiesbaden, Germany) were coated with buffer solution containing 50 mmollL NaCOi NaHC03, 0.05% sodium azide, and 0.5 fLg/mL anti-NGF monoclonal antibody (Boehringer Mannheim, Mannheim, Ger many) for 2 hours at 20°C. Nonspecific binding sites were saturated with I % bovine serum albumin, and the wells were washed three times with a wash buffer (50 mmollL Tris-HCl, 200 mmollL NaCI, 10 mmol/L CaCI2, 0.1 % Triton X-I 00, and 0.1 % sodium azide, pH 7.0). The extracted samples and stan dard solution were added, and the plates were incubated for 5 hours at 20°C followed by three washings with wash buffer. The [3-galactosidase-conjugated anti-NGF antibody (Boeh ringer Mannheim) was added, and the plates were kept at 4°C overnight. After washing with wash buffer, the substrate solu tion containing 20 fLg/mL 4-methylumbelliferyl-[3-D galactoside (Sigma, St. Louis, MO, U.S.A.) was added. The plate was incubated again for 5 hours at 20°C. The measure ment of NGF was performed with the fluorospectrophotometer (BIO-TEK, Germany). The wavelengths for excitation and emission were set at 360 and 450 nm, respectively. Standard curves were prepared with 2.5 S NGF standard purified from mouse submaxillary gland by assaying parallel wells contain ing increasing amounts of NGF (0 to 500 pg/mL). The content of NGF in the samples was calculated from the standard curve.
RESULTS
Transient forebrain ischemia in rats
After 10 minutes of global ischemia, a progressive neuronal cell death was observed in the hippocampal CAl subfield (Fig. 1) . Twenty-four hours after reperfu sion, no detectable neuronal damage was found in the hippocampus. Two days after ischemia, about 41 % of the neurons in the CAl region were injured. By the fourth day after ischemia, the percentage of damaged neurons in the hippocampus reached a plateau of more than 90% that was unchanged 7 days after ischemia. Intraperitoneal treatment with clenbuterol 3 hours be fore ischemia or immediately after ischemia reduced the CAl neuronal damage measured 7 days after ischemia (Fig. 2) . The neuronal damage in CAl subfield was un affected by the treatment with 0.1 mg/kg clenbuterol. Pretreatment with both 0.5 and 1.0 mg/kg clenbuterol resulted in a reduced neuronal loss. The former treatment reduced the number of damaged neurons in CA l region by 23% (P < 0.01) and the latter by 15% (P < 0.05). The immediate injection of 0.5 mg/kg clenbuterol after isch emia (posttreatment) showed a similar neuroprotective effect (P < 0.05).
Compared with the control, animals treated with 0.5 and 1.0 mg/kg of clenbuterol showed a reduction of blood pressure to 85% (P < 0.05) and 70% (P < 0.001), respectively. The blood glucose level in the group treated with 1.0 mg/kg clenbuterol was significantly elevated by 7l.2% (P < 0.001).
DNA fragmentation assay
The time courses of DNA fragmentation after global ischemia are presented in Fig. 3 from the hippocampus, striatum, and cortex of normal animals ( Fig. 3A through C, lane 2) was preserved. On the first day after ischemia, DNA laddering was detect able only in the striatum (Fig. 3C, lane 3) . No internu cleo somal DNA cleavage was seen in hippocampus and cortex ( Fig. 3A and B, lane 3) . A typical DNA laddered pattern with oligonucleosomal fragments of 180 base pair and its multiples was observed in hippocampus and striatum on days 2 and 3 ( Fig. 3A and C, lanes 4 and 5) and in the cortex on day 3 after ischemia (Fig. 3B, lane   4) . The DNA fragmentation was reduced in all three regions at day 4 ( Fig. 3A and C, lane 6; Fig. 3B, lane 5) .
The intensity of DNA laddering in the striatum was more pronounced than in the hippocampus and cortex.
Based on these results, clenbuterol (0.5 mg/kg intra peritoneally) was administered 3 hours before ischemia.
Three days after ischemia, the DNA from the hippocam pus, striatum, and occipital cortex was prepared for DNA fragmentation assay. The effect of clenbuterol against DNA degradation is shown in Fig. 4 . The typical DNA ladders of approximately 180 base pair and its multiples in the control group (Fig. 4, lanes 1, 3, and 5 ) confirm the results presented in the time course of DNA fragmenta tion (Fig. 3) . In the hippocampus, the DNA fragmenta tion was nearly abolished after the treatment with clen buterol (Fig. 4, lane 4) . Clenbuterol partially blocked the DNA fragmentation in occipital cortex and striatum (Fig.   4, lanes 2 and 6) . The protective effect of clenbuterol against DNA degradation in all of these regions investi gated after global ischemia was confirmed by two re peated experiments.
The result from TUNEL staining is shown in Fig. 5 . In the control group (n = 3), which was subjected to 10minute global ischemia followed by 3 days of recovery, extensively positively stained neurons were localized in the CAl subfield of the hippocampus and in the striatum ( Fig. 5A and C) . In comparison, the number of positively stained neurons in the clenbuterol-treated group (n = 3) was smaller than in the corresponding region of the con trols and the intensity of staining was much weaker than in the control group (Fig. 5B and D) .
Measurement of nerve growth factor protein
The content of NGF protein in the hippocampus, cor tex, and striatum 6 hours and 3 days after ischemic insult is shown in Fig. 6A . Clenbuterol (0.5 mg/kg) injected 3 hours before global ischemia elevated the NGF protein by 33.1 % (P < 0.05) in the hippocampus and 44.4% (P < 0.05) in the cortex compared with the control group when measured 6 hours after ischemia. However, no sig nificant increase of NGF was found in striatum ( Fig.   6A ). Three days after ischemia, the NGF levels in both clenbuterol-treated groups (0.5 mg/kg and 0.5 mg/kg x 4) were not different from controls (Fig. 6A and B ).
DISCUSSION
In various models of transient global ischemia, a se lective and delayed neuronal cell death in the vulnerable CA I subfield of the hippocampus has been demon strated. The time course of neuronal damage in CA 1 subfield after 10-minute forebrain ischemia showed that the neuronal damage could be detected 2 days after isch emia, and the peak of the cell death occurred 3 to 4 days after ischemia (Fig. I) .
In the present study, a single intraperitoneal injection of c1enbuterol was administered. Both doses of clen buterol (0.5 mg/kg before and after treatment; 1.0 mg/kg pretreatment only) demonstrated neuroprotective activi ties. Hypotension and increased blood glucose concen tration were found in the animals that were treated with 1.0 mg/kg clenbuteroI. Increased blood glucose concen tration has been suggested to accelerate tissue acidosis during ischemia and aggravate the neuronal damage (Smith et a!., 1984; Warner et a!., 1987; Smith et aI., 1988) . This could explain why treatment with 1.0 mg/kg clenbuterol caused a smaller neuroprotective effect than the lower dosage (0.5 mg/kg) (Fig. 2) .
It has been previously reported that apoptosis is in volved in the delayed neuronal death in the CAl pyra midal cell layer of the hippocampus after global ischemia (Nitatori et a!., 1995; Wiessner et a!., 1996) . cleavage products, which appear as a DNA ladder in the electrophoresis (Arends et aI., 1990; Tominaga et a!., 1993; Siesjo et aI., 1995) . Thus, the DNA laddering is considered as the biochemical hallmark of apoptosis (Heron et aI., 1993; MacManus et aI., 1995) . The time courses of DNA fragmentation in the hippocampus, stria tum, and occipital cortex obtained in this study revealed that a typical DNA laddering pattern appeared first in the striatum 1 day after ischemia and occurred subsequently in the hippocampus on day 2 and in the occipital cortex on day 3 after ischemia. The peak of the DNA fragmen tation in striatum, hippocampus, and cortex appeared 3 days after onset of ischemia. The DNA fragmentation occurred earlier in the striatum than in the hippocampus, and the intensity of DNA fragmentation in the striatum also was stronger than in either the hippocampus or the cortex. Results from TUNEL staining revealed exten sively positive stained cells in the hippocampus and striatum 3 days after ischemia. By observing the mor- suggesting DNA fragmentation could appear in the nu clei before the morphologic alterations observed in apop totic cells. We can thus conclude that the delayed neu ronal death or apoptosis after global ischemia is not only present in the CA I subfield but also in the striatum. The latter seems to be especially susceptible to apoptosis.
In necrotic cells, the large degraded DNA fragments, which result from activation of hydrolytic enzymes in dead cells, usually show a smearing pattern (Afanas'ev et aI., 1986; Bicknell and Cohen, 1995; MacManus et aI., 1995) . In our experiment, a typical DNA laddering with smearing was found in control animals ( Figs. 3 and 4,  lanes 1, 3, 5) . These results suggest that both apoptosis and necrosis are present in ischemic brain tissue after global ischemia. It is difficult to estimate the percentages of apoptotic cells or necrotic cells in the total number of damaged cells induced by global ischemia. In situ end labeling merely indicates the presence of DNA breaks that provide an available 3'-OH end. This may occur in both apoptotic and necrotic cells, so the TUNEL staining alone cannot determine the mechanism of cell death (Wi jsman et aI., 1993; Charriaut-Marlangue et aI., 1995) .
Nevertheless, the DNA laddering is considered as a dis tinct characteristic of apoptosis.
In this study, we clearly demonstrate that 0.5 mg/kg of c1enbuterol significantly blocked the DNA laddering in ischemic brain tissue (Fig. 4, lanes 2, 4, and 6) . The TUNEL staining also showed that the number of posi tively stained cells in the c1enbuterol-treated group is reduced and the intensity of the staining is much weaker than in the control group. These results prove that c1en buterol can efficiently antagonize apoptosis in all three brain regions studied here after global ischemia. On the other hand, a reduced DNA smearing pattern also was found in c1enbuterol-treated animals. Combining the re- -517-394-298-220-154 FIG. 4 elenbuterol prevents DNA fragmentation in hippocampus (H), striatum (8), and cortex (e) after 10-minute transient global ischemia. elenbuterol (0.5 mg/kg) was intraperitoneally adminis tered 3 hours before ischemia. Rat brains were removed 3 days after ischemia, and DNA was extracted from hippocampus, stria tum, and cortex. Animals in the control group received saline. Lane 1: digoxigenin-Iabeled marker; lanes 2, 4, and 6: clen buterol-treated ischemic animals; lanes 3, 5, and 7: untreated ischemic animals . suIts obtained in this study with our previous findings that clenbuterol protects neuronal damage induced by excitotoxicity or focal ischemia (Semkova et aI., 1994; Semkova et aI., 1996a) , we conclude that clenbuterol is able to attenuate necrosis as well.
653
Nerve growth factor is one of the best characterized neurotrophic factors that supports the growth, differen tiation, and survival of neurons within both the periph eral and central nervous systems (Korsching et aI., 1985; Rennert and Heinrich, 1986; Whittemore et aI., 1986; Longo et aI., 1993) . Our previous studies showed that the stimulation of �2-adrenergic receptor by clenbuterol could attenuate the damage of cultured neurons by in creasing synthesis of NGF. We further attempted to find out whether this drug could elevate the NGF protein content in the brain subjected to transient forebrain isch emia and whether induction of NGF synthesis by clen buterol is associated with its antiapoptotic effect in the rat model of global ischemia.
The results showed that clenbuterol significantly el evated the NGF protein in the hippocampus and the oc cipital cortex, but not in the striatum 6 hours after the buterol (0.5 mg/kg intraperitoneally) 3 hours before ischemia as well as 1, 2, and 3 days after ischemia. The brains were removed 3 days after ischemia for NGF measurement. The control group was treated with saline in the same way (n = 4 for each group). The values are presented as means ± SO. *P < 0.05 compared with control (Student's t-test).
ischemic insult. Three days after ischemia, the NGF lev els were no longer elevated in the clenbuterol-treated groups (0.5 mg/kg and 0.5 mg/kg x 4) when compared with the controls. We observed that after 3 days of re covery, the raised NGF level in controls was most likely induced by ischemia itself in the hippocampus and cor tex. Furthermore, repeated treatment with c1enbuterol may lead to a down-regulation of I)-adrenergic receptors, which could limit NGF induction (Murugaiah and O'Donnell, 1994; Newmantancredi et aI., 1996) .
Our results suggest that the enhanced NGF synthesis by c1enbuterol is detectable, especially at earlier time periods. Thus, we suggest that the NGF synthesis in creased by c1enbuterol in the initial first hours after isch emia might be important for the prevention of DNA deg- radation and the support of neuronal survival. The sta bilization of the intracellular calcium homeostasis (Cheng and Mattson, 1991; Mattson et aI., 1993; Mattson and Cheng, 1994) and the upregulation of the antiapop totic protooncogene bcl-2 (Katoh et aI., 1996; Lezoualc'h et aI., 1996; Zhai et aI., 1996) also may be involved in the neuroprotective activity of NGF.
In conclusion, this study clearly demonstrates that clenbuterol possesses a neuroprotective activity and a pronounced capacity to block the DNA degradation after global ischemia. We demonstrate for the first time that c1enbuterol is able to antagonize apoptosis induced by transient global ischemia. Thus, the pharmacologic in duction of endogenous NGF synthesis in brain tissue could become a new therapeutic strategy for neurode generative diseases and brain insults that are associated with apoptotic cell death. 
